Loading...

Medios AG

ILM1.DE•XETRA
Healthcare
Medical - Distribution
€12.48
€-0.28(-2.19%)

Medios AG (ILM1.DE) Stock Overview

Explore Medios AG’s financial performance, market position, analyst ratings, and future outlook.

Meyka AI Score

F

Score: N/A

Key Financials

Market Cap318.3M
P/E Ratio21.33
EPS (TTM)$0.59
ROE0.03%
Fundamental Analysis

AI Price Forecasts

1 Week$12.00
1 Month$12.45
3 Months$12.33
1 Year Target$12.13

ILM1.DE Stock Analysis & Investment Overview

Our comprehensive AI-powered analysis of Medios AG (ILM1.DE) provides investors with deep insights into the stock's performance, growth potential, and market positioning. With a Meyka AI Score of F, this stock demonstrates moderate investment characteristics based on our advanced machine learning models.

The current technical analysis reveals key indicators including an RSI of 59.52, suggesting the stock is in a neutral condition. Our forecasting models predict significant price movements, with a 12-month target of $12.13.

Key financial metrics showcase the company's fundamental strength, including a P/E ratio of 21.33 and a market capitalization of 318.3M. These metrics, combined with our AI analysis, provide a comprehensive view for both institutional and retail investors.

Technical Indicators

59.52RSI (14)
0.27MACD
21.17ADX
Revenue Growth
5.51%
↑ 5.51%
Profit Growth
€0.59
↓ 33.29%
EPS Growth
€0.59
↓ 35.44%
Operating Margin
1.96%
↑ 0.94%
ROE
2.93%
↓ 33.29%
Dividend Yield
0.00%
Analyst Recommendations data is not available for ILM1.DEAnalyst Recommendations details for ILM1.DE are currently unavailable. We're actively monitoring for updates and will publish them as soon as they’re released. Please check back again shortly.

Company Profile

Medios AG, together with its subsidiaries, engages in the wholesale of specialty pharmaceutical drugs in Germany. It operates through Pharmaceutical Supply and Patient-Specific Therapies segments. The Pharmaceutical Supply segment offers products on oncology, neurology, autoimmunology, ophthalmology, infectiology, and hemophilia diseases. The Patient-Specific Therapies segment manufactures medications for patients on behalf of pharmacies; and patient-specific therapies for dispensing individually dosed tablets. The company was founded in 2016 and is based in Berlin, Germany.

CEO

Matthias Gaertner

Employees

472

Headquarters

Heidestrasse 9, Berlin

Founded

2007

Frequently Asked Questions

;